10-Q: Gain Therapeutics Q3 2025 Loss; Parkinson's Study Extended

Gain Therapeutics reported a net loss of $15.6 million for the nine months ended September 30, 2025, while extending its Phase 1b Parkinson's disease study due to positive participant retention.

Summary

• The company reported a net loss of $15.6 million for the nine months ended September 30, 2025, an improvement from a $16.6 million net loss for the same period in 2024.
• For the three months ended September 30, 2025, the net loss increased to $5.3 million compared to $4.5 million for the same period in 2024.
• Cash and cash equivalents stood at $8.8 million as of September 30, 2025, down from $10.4 million at December 31, 2024.
• An accumulated deficit of $96.8 million was reported as of September 30, 2025, up from $81.2 million at December 31, 2024.
• Management has raised substantial doubt about the company's ability to continue as a going concern beyond the first quarter of 2026 without additional funding.
• The Phase 1b clinical study for GT-02287 in Parkinson's disease patients showed the drug was generally well tolerated with no treatment-emergent serious adverse events.
• Participants in the GT-02287 open label trial appear to be benefitting from stabilization and trending improvements in their MDS-UPDRS scores after 90 days of administration.
• The open label study for GT-02287 was extended for an additional 9 months in September 2025, with the majority of participants electing to remain on the extension.
• The company completed a public offering in July 2025, raising $6.0 million in net proceeds, and sold shares under its 2024 ATM Program for $4.91 million net proceeds during the nine months ended September 30, 2025.
• Stockholders approved an amendment on June 24, 2025, to increase authorized common stock from 50 million to 100 million shares.

Sentiment

Score: 3

Explanation: While there are positive early clinical updates for GT-02287 and successful capital raises, the company faces significant financial challenges, including recurring losses, negative cash flows, and an explicit going concern warning, indicating a high need for further capital to sustain operations. This creates substantial uncertainty for investors.

Positives

• GT-02287 Phase 1b clinical study in Parkinson's disease patients demonstrated general tolerability and no treatment-emergent serious adverse events.
• Participants in the open label trial for GT-02287 showed stabilization and trending improvements in MDS-UPDRS scores after 90 days.
• The majority of participants elected to remain on the GT-02287 open label extension study for an additional 9 months, indicating positive reception and potential efficacy.
• Net loss for the nine months ended September 30, 2025, decreased to $15.6 million from $16.6 million in the prior year, reflecting some operational efficiencies.
• Cash provided by financing activities increased to $11.9 million for the nine months ended September 30, 2025, from $10.7 million in the prior year, indicating successful capital raises.

Negatives

• The company has incurred recurring losses and negative cash flows from operations since inception, with an accumulated deficit of $96.8 million as of September 30, 2025.
• Existing cash and cash equivalents of $8.8 million as of September 30, 2025, are not sufficient to fund estimated operating and capital expenditures for at least 12 months, raising substantial doubt about the ability to continue as a going concern beyond Q1 2026.
• Net loss for the three months ended September 30, 2025, increased to $5.3 million from $4.5 million in the prior year.
• Research and development expenses increased by $0.2 million for the three months ended September 30, 2025, primarily due to ongoing clinical trial costs and unfavorable foreign exchange currency translation.
• General and administrative expenses increased by $0.1 million for the three months ended September 30, 2025, driven by higher stock-based compensation, personnel costs, and unfavorable foreign exchange.
• Foreign exchange loss, net, increased by $0.9 million to a loss of $0.7 million for the nine months ended September 30, 2025, due to the strengthening Swiss franc and Australian dollar against the U.S. dollar.
• Income taxes increased significantly to $791 thousand for the nine months ended September 30, 2025, from $32 thousand in the prior year, mainly due to higher corporate taxes in Australia.
• Two tranches of warrants, totaling 425,387 warrants, were forfeited in May and July 2025, respectively, as they were not exercised within their exercisable periods.

Risks

• The company's ability to continue as a going concern is in substantial doubt due to recurring losses and insufficient cash to fund operations for the next 12 months.
• There is a risk of not being able to obtain additional financing on acceptable terms, or at all, which could lead to delays, reductions, or termination of R&D programs.
• The company is subject to risks common to early-stage biotechnology companies, including the completion and success of preclinical studies and clinical testing.
• Dependence on key personnel and the ability to protect proprietary technology are critical risks.
• Compliance with applicable governmental regulations and the development of new technological innovations by competitors pose ongoing challenges.
• Uncertainty exists regarding when, if ever, the company will realize revenue from product sales, even if drug development efforts are successful.
• Macroeconomic conditions, including inflation, fluctuating interest rates, geopolitical tensions (e.g., Ukraine, Hamas-Israel conflicts), exchange rate fluctuations, supply chain disruptions, and increases in commodity, energy, and fuel prices, may impact operations and access to financing.
• Inadequate funding or disruptions at regulatory agencies (FDA, SEC, EMA) due to government shutdowns or policy changes could delay product development and commercialization.

Future Outlook

The company anticipates incurring additional losses until it can generate significant sales of its product candidates currently in development. Substantial additional capital will be needed to fund operations and develop product candidates. Management plans to raise additional capital primarily through private and/or public equity financings and/or convertible debt financings, and is actively seeking opportunities for strategic collaborations, licensing agreements, and grant fundings. Research and development expenses are expected to increase substantially in future periods to support progress in research and development activities, including the progression of clinical trials for product candidates.

Management Comments

• "We continue to monitor the impacts on our operations and access to financing, global and worsening macroeconomic conditions, such as the war in Ukraine, the Hamas-Israel conflict, global geopolitical tension, exchange rate fluctuations, supply chain disruptions, liquidity concerns and increases in commodity, energy and fuel prices."
• "Our current operating plan indicates that we will continue to incur losses from operations and negative cash flows from operating activities. Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report. We will need to raise additional capital to fund continued operations beyond the first quarter of 2026."
• "We plan to address our liquidity needs by taking steps to improve our operations and cash position, including identifying access to future capital and potential cost-reduction measures."

Industry Context

Gain Therapeutics operates in the early-stage biotechnology industry, focusing on developing novel small molecule therapeutics for central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases targeted through protein degradation, such as oncology. The company leverages its proprietary Magellan drug discovery platform to identify allosteric binding sites. This sector is characterized by high research and development costs, long development cycles, and significant capital requirements, with success heavily reliant on positive clinical trial outcomes and regulatory approvals. The company's lead candidate, GT-02287, targets Parkinson's disease, a competitive and high-need area within neurodegenerative disorders.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are mentioned in the filing for direct assessment against global benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• Litigation was filed by former Chief Executive Officer Matthias Alder on September 18, 2024, in the Circuit Court of Maryland for Montgomery County, following his employment termination on June 25, 2024. The lawsuit was dismissed with prejudice on July 2, 2025, after mediation, with accrued amounts materially in line with settlement disbursements.

Related Party Transactions

• Dr. Khalid Islam, the Executive Chairman of the Board and founder of the company, is also the Chairman of the Board of Directors of Minoryx Therapeutics SL, making Minoryx a related party.
• In December 2017, the company entered into an exclusive worldwide license agreement with Minoryx Therapeutics SL to use and exploit Minoryx's intellectual property.
• There were no receivables or payables with Minoryx as of September 30, 2025, and December 31, 2024.
• There were no revenues or expenses for the nine months ended September 30, 2025, and 2024 with Minoryx.

Stakeholder Impact

• Shareholders face potential significant dilution from ongoing and future equity financings due to the critical need for additional capital. There is a risk of substantial or total loss of investment if the company is unable to secure sufficient funding to continue operations.
• Employees may experience uncertainty regarding job security given the company's going concern warning, though stock-based compensation plans are in place.
• Future customers could benefit from new therapeutic options for Parkinson's disease and other disorders if product candidates are successfully developed and commercialized.
• Creditors face increased risk due to the company's recurring losses, negative cash flows, and explicit going concern warning, which highlights reliance on future capital raises.

Next Steps

• Continue to advance existing research programs and initiate additional programs targeting allosteric binding sites identified with the Magellan platform.
• Further develop GT-02287 in GBA1 Parkinson's patients following positive Phase 1 results.
• Continue the extended open label study for GT-02287 for an additional 9 months.
• Obtain additional capital and/or other funding to continue operations beyond the first quarter of 2026.
• Review the cost structure throughout the organization to optimize expenditures and improve the overall cash burn rate.
• Actively seek opportunities for strategic collaborations, licensing agreements, and grant fundings.
• Progress clinical trials for current product candidates and discover and develop additional product candidates.
• Pursue later stages of clinical development for product candidates.

Key Dates

Recommendation

The company faces substantial doubt about its ability to continue as a going concern beyond Q1 2026, indicating a critical liquidity crisis. Despite recent capital raises and some positive early clinical data for GT-02287, the recurring losses, negative cash flows, and the explicit need for significant additional financing present an extremely high-risk profile. The ongoing dilution from equity offerings and the uncertainty of future funding make the stock a speculative investment with significant downside risk for a seasoned investor, warranting a sell recommendation.

Keywords

biotechnology, Parkinson's disease, GT-02287, clinical trial, Phase 1b, going concern, capital raise, Magellan platform, neurodegenerative disorders, small molecule therapeutics, SEC filing, 10-Q, drug discovery, GBA1 mutations